ABL1 and amyotrophic lateral sclerosis: Bosutinib also increased survival in vitro of ALS iPSC-derived motor neurons from patients with sporadic ALS, bosutinib treatment modestly extended survival of a mouse model of ALS with an SOD1 mutation, suggesting that Src/c-Abl may be a potentially useful target for developing new drugs to treat ALS (Imamura et al., 2017).